The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-04. Anything still debated is marked as such rather than presented as settled.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
In February 2010, the FDA's associate director of drug safety, recommended rosiglitazone be taken off the market. In June 2010, they published a retrospective study comparing roziglitazone to pioglitazone, the other thiazolidinedione marketed in the United States and concluded rosiglitazone was associated with "an increased risk of stroke, heart failure, and all-cause mortality and an increased risk of the composite of AMI, stroke, heart failure, or all-cause mortality in patients 65 years or older". The number needed to harm with roziglitazone was sixty. Graham argued rosiglitazone caused 500 more heart attacks and 300 more heart failures than its main competitor. Two meta analyses released in 2010, one incorporating 56 trials and a second incorporating 164 trials reached conflicting conclusions. Nissen et al. found again an increased risk for heart infarction against control, but no increased risk for cardiovascular death. Mannucci et al. found no statistically significant increase in cardiac events but a significant increase in heart failure. A 2011 drug class review found an increased risk of cardiovascular adverse events. A meta-analysis of 16 observational studies released in March, 2011, compared rosiglitazone to pioglitazone, finding support for greater cardiovascular safety for pioglitazone. The meta-analysis involved 810 000 patients taking rosiglitazone or pioglitazone. The study suggests 170 excess myocardial infarctions, 649 excess cases of heart failure, and 431 excess deaths for every 100 000 patients who receive rosiglitazone rather than pioglitazone.
== Formation of racemic mixtures == Racemization can be achieved by simply mixing equal quantities of two pure enantiomers. Racemization can also occur in a chemical interconversion. For example, when (R)-3-phenyl-2-butanone is dissolved in aqueous ethanol that contains NaOH or HCl, a racemate is formed. The racemization occurs by way of an intermediate enol form in which the former stereocenter becomes planar and hence achiral. An incoming group can approach from either side of the plane, so there is an equal probability that protonation back to the chiral ketone will produce either an R or an S form, resulting in a racemate. Racemization can occur through some of the following processes:
Potassium ions are an essential component of plant nutrition and are found in most soil types. They are used as a fertilizer in agriculture, horticulture, and hydroponic culture in the form of chloride (KCl), sulfate (K2SO4), or nitrate (KNO3), representing the 'K' in 'NPK'. Agricultural fertilizers consume 95% of global potassium chemical production, and about 90% of this potassium is supplied as KCl. The potassium content of most plants ranges from 0.5% to 2% of the harvested weight of crops, conventionally expressed as amount of K2O. Modern high-yield agriculture depends upon fertilizers to replace the potassium lost at harvest. Most agricultural fertilizers contain potassium chloride, while potassium sulfate is used for chloride-sensitive crops or crops needing higher sulfur content. The sulfate is produced mostly by decomposition of the complex minerals kainite (MgSO4·KCl·3H2O) and langbeinite (MgSO4·K2SO4). Only a very few fertilizers contain potassium nitrate. In 2005, about 93% of world potassium production was consumed by the fertilizer industry. Furthermore, potassium can play a key role in nutrient cycling by controlling litter composition.
Reith revealed in a 2009 letter to the Journal of the Royal College of Physicians of Edinburgh that she and her colleagues made no money from the invention, with the then Greater Glasgow Health Board holding the patent on their behalf and receiving income until it sold the rights to pharmaceutical company Novo.
Sources: en.wikipedia.org
=== Drug–drug interactions with siRNA therapeutics === As the number of approved RNAi therapeutics has grown, reaching seven in 2025 (patisiran, givosiran, lumasiran, inclisiran, vutrisiran, nedosiran, and fitusiran), a distinct challenge has emerged in assessing drug–drug interactions (DDIs) for this drug class. Unlike small-molecule drugs, siRNA therapeutics are not major substrates of cytochrome P450 enzymes and do not rely on classical hepatic or renal uptake transporters. Instead, they are metabolized by endogenous endo- and exonucleases to shortened oligonucleotide chains, and their systemic pharmacokinetic parameters often do not reflect target-tissue distribution or pharmacodynamic (PD) outcomes. A clinically observed example of an unexpected DDI is givosiran, which produced a 2- to 3-fold increase in systemic exposure to cytochrome P450 substrates dextromethorphan (CYP2D6) and caffeine (CYP1A2) in patients with acute intermittent porphyria—an effect not predicted by standard in vitro CYP enzyme studies. The proposed mechanism involves indirect interference with hepatic heme biosynthesis via on-target suppression of aminolevulinate synthase 1 (ALAS1), rather than direct enzyme inhibition. More broadly, siRNA drugs may compete with endogenous microRNAs (miRNAs) for shared components of the RNA-induced silencing complex (RISC), particularly Argonaute (AGO) proteins.
==== Combined malonic and methylmalonic aciduria (CMAMMA) ==== In the metabolic disease combined malonic and methylmalonic aciduria (CMAMMA) due to ACSF3 deficiency, there is an altered composition of complex lipids as a result of impaired mitochondrial fatty acid synthesis (mtFAS), so for example the content of cardiolipins is strongly increased.
In organisms that use chromosomal crossover to exchange DNA and recombine genes, errors in alignment during meiosis can also cause mutations. Errors in crossover are especially likely when similar sequences cause partner chromosomes to adopt a mistaken alignment; this makes some regions in genomes more prone to mutating in this way. These errors create large structural changes in DNA sequence—duplications, inversions, deletions of entire regions—or the accidental exchange of whole parts of sequences between different chromosomes, chromosomal translocation.
The last of the Boers finally surrendered in late May 1902 and the war ended with the Treaty of Vereeniging signed on 31 May 1902. After a period of obstinacy, the British offered the Boers generous terms of conditional surrender in order to bring the war to a conclusion. The Boers were given £3,000,000 (equivalent to £319,000,000 in 2025) for reconstruction and promised eventual limited self-government, which was granted in 1906 and 1907. The treaty ended the existence of the Transvaal and Orange Free State as independent Boer republics and placed them within the British Empire. The Union of South Africa was established as a dominion of the British Empire in 1910.
==== MeSH D12.125.166 – amino acids, sulfur ==== MeSH D12.125.166.175 – cystathionine MeSH D12.125.166.215 – cysteic acid MeSH D12.125.166.230 – cysteine MeSH D12.125.166.230.259 – acetylcysteine MeSH D12.125.166.230.310 – carbocysteine MeSH D12.125.166.230.330 – cysteinyldopa MeSH D12.125.166.230.369 – cystine MeSH D12.125.166.230.700 – selenocysteine MeSH D12.125.166.388 – ethionine MeSH D12.125.166.498 – homocysteine MeSH D12.125.166.498.050 – s-adenosylhomocysteine MeSH D12.125.166.554 – homocystine MeSH D12.125.166.676 – methionine MeSH D12.125.166.676.180 – s-adenosylmethionine MeSH D12.125.166.676.450 – n-formylmethionine MeSH D12.125.166.676.450.440 – n-formylmethionine leucyl-phenylalanine MeSH D12.125.166.676.620 – methionine sulfoximine MeSH D12.125.166.676.620.125 – buthionine sulfoximine MeSH D12.125.166.676.900 – selenomethionine MeSH D12.125.166.676.950 – vitamin u MeSH D12.125.166.786 – penicillamine MeSH D12.125.166.786.500 – s-nitroso-n-acetylpenicillamine MeSH D12.125.166.800 – thiopronine MeSH D12.125.166.893 – thiorphan
Sources: en.wikipedia.org
Using typical doses, ampicillin/sulbactam has been shown to reach desired levels to treat infections in the brain, lungs, and abdominal tissues. Both agents have moderate protein binding, reported at 38% for sulbactam and 28% for ampicillin.15,16 The half-life of ampicillin is approximately 1 hour, when used alone or in combination with sulbactam; therefore it will be eliminated from a healthy person in around 5 hours. It is eliminated primarily by the urinary system, with 75% excreted unchanged in the urine. Only small amounts of each drug were found to be excreted in the bile. Ampicillin/sulbactam should be given with caution in infants less than a week old and premature neonates. This is due to the underdeveloped urinary system in these patients, which can cause a significantly increased half-life for both drugs.16 Based on its elimination, ampicillin/sulbactam is typically given every 6 to 8 hours. Slowed clearance of both drugs has been seen in the elderly, renal disease patients, and critically ill patients on renal replacement therapy. Reduced clearance has been seen in both pediatric and post-operative patients. Adjustments in dosing frequency may be required in these patients due to these changes.
==== Cancer ==== While traditional chemotherapy can effectively kill cancer cells, lack of specificity for discriminating normal cells and cancer cells in these treatments usually cause severe side effects. Numerous studies have demonstrated that RNAi can provide a more specific approach to inhibit tumor growth by targeting cancer-related genes (i.e., oncogene). It has also been proposed that RNAi can enhance the sensitivity of cancer cells to chemotherapeutic agents, providing a combinatorial therapeutic approach with chemotherapy. Another potential RNAi-based treatment is to inhibit cell invasion and migration. Compared with chemotherapy or other anti-cancer drugs, there are a lot of advantages of siRNA drug. SiRNA acts on the post-transcriptional stage of gene expression, so it does not modify or change DNA in a deleterious effect. SiRNA can also be used to produce a specific response in a certain type of way, such as by downgrading suppression of gene expression. In a single cancer cell, siRNA can cause dramatic suppression of gene expression with just several copies. This happens by silencing cancer-promoting genes with RNAi, as well as targeting an mRNA sequence. RNAi drugs treat cancer by silencing certain cancer promoting genes. This is done by complementing the cancer genes with the RNAi, such as keeping the mRNA sequences in accordance with the RNAi drug. Ideally, RNAi is should be injected and/or chemically modified so the RNAi can reach cancer cells more efficiently. RNAi uptake and regulation is controlled by the kidneys.
A parathyroid adenoma is the most common cause of hyperparathyroidism. They are more commonly found in women than in men. In this form, the chief cells mutate to exhibit multiple nuclei. Chief cells in parathyroid adenomas also display acid phosphatase activity. It is a benign tumor of the gland that requires surgical removal. These benign adenomas are typically affect only one or two of the parathyroid glands, known respectively as a single adenoma or double adenoma. Typically, no disease is linked to the cause. A primary adenoma can only develop as a primary cause.
== In popular culture == A fictionalized version of the Black Dragon Society "featured in much of American popular culture". It appeared in Master Comics starting with issue 21, first published by Fawcett Comics on December 10, 1941. Initially displayed as an external threat, the Black Dragon Society was given elements of a fifth column after the attack on Pearl Harbor, which reflected the fear of subversion of American society by Japanese-Americans. In DC's All Star Comics from 1942 the Society functioned as an opponent of the Justice Society of America and were likewise presented as an example of "alleged Japanese American perfidy". Another fictionalized version of the Black Dragon Society is featured in the CBS television series Raven, where they are a ninja clan operating in Hawaii.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.